NASDAQ:XTLB - Nasdaq - US98386D3070 - ADR - Currency: USD
NASDAQ:XTLB (5/21/2025, 4:30:02 PM)
1.05
-0.05 (-4.55%)
The current stock price of XTLB is 1.05 USD. In the past month the price decreased by -13.58%. In the past year, price decreased by -59.77%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.7 | 321.60B | ||
AMGN | AMGEN INC | 13.07 | 145.89B | ||
GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.54B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
BIIB | BIOGEN INC | 8.02 | 18.58B |
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
XTL BIOPHARMACEUTICALS-ADR
5 Badner St., P.O.Box 8241
Ramat Gan 4365603 IL
CEO: Shlomo Shalev
Employees: 33
Phone: 97299557080
The current stock price of XTLB is 1.05 USD. The price decreased by -4.55% in the last trading session.
The exchange symbol of XTL BIOPHARMACEUTICALS-ADR is XTLB and it is listed on the Nasdaq exchange.
XTLB stock is listed on the Nasdaq exchange.
XTL BIOPHARMACEUTICALS-ADR (XTLB) has a market capitalization of 5.72M USD. This makes XTLB a Nano Cap stock.
XTL BIOPHARMACEUTICALS-ADR (XTLB) currently has 33 employees.
XTL BIOPHARMACEUTICALS-ADR (XTLB) has a resistance level at 1.39. Check the full technical report for a detailed analysis of XTLB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XTLB does not pay a dividend.
The outstanding short interest for XTL BIOPHARMACEUTICALS-ADR (XTLB) is 0.93% of its float. Check the ownership tab for more information on the XTLB short interest.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |